Adam predicts positive trial results. Also, he polled 12 professional healthcare investors, and 10 of the 12 (83%) predict a positive outcome.
Here is the link to the article:
http://www.thestreet.com/story/11998433/1/mannkind-vical-gtx-investors-predict-pivotal-clinical-trial-results.html